"Our focus is ensuring that we are able to get approvals for all the
necessary studies and data in India. We will be able to provide the
drug once the Indian approvals come through. This is our main
bottleneck now," said R Ananthanarayanan.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-awaiting-govt-nod-for-favipiravir-says-ceo-r-ananthanarayanan/articleshow/75463029.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment